BioCryst Pharmaceuticals BCRX Business Segments — Interest Income, Operating
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeOperating.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's business segments — interest income, operating.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's business segments — interest income, operating?
- BioCryst Pharmaceuticals (BCRX) reported business segments — interest income, operating of $2.26M in Q1 2026.
- How has BioCryst Pharmaceuticals's business segments — interest income, operating changed year-over-year?
- BioCryst Pharmaceuticals's business segments — interest income, operating decreased by 25.4% year-over-year, from $3.02M to $2.26M.
- What is the long-term trend for BioCryst Pharmaceuticals's business segments — interest income, operating?
- Over 2 years (2023 to 2025), BioCryst Pharmaceuticals's business segments — interest income, operating has grown at a -17.8% compound annual growth rate (CAGR), from $15.78M to $10.67M.
- What does business segments — interest income, operating mean?
- Includes interest earned on cash balances, cash equivalents, and marketable securities held by the segment. It reflects the segment's ability to generate supplemental income from its liquid assets.